Storing Foxo4 Dri: Best Practices
Lyophilized Powder
Store at -20°C or lower to maintain stability. The lyophilized form is highly stable due to D-amino acid composition. Keep sealed, away from moisture and light.
Reconstituted Solution
Dissolve in PBS (Phosphate Buffered Saline) or sterile water. Prepare stock solutions at 2 mM or 5 mg/mL. Keep reconstituted solutions on ice and use promptly. Aliquot stock solutions to prevent freeze-thaw cycles which may degrade the peptide despite its protease resistance.
Handling
White lyophilized powder, typically supplied as a TFA (trifluoroacetic acid) salt. Purity: ≥95–98% by HPLC. Identity: Mass Spectrometry (~5358.05 Da). The D-Retro-Inverso modification provides exceptional resistance to proteolytic degradation, with intracellular detection up to 72 hours post-administration.
Referencias
- Baar MP, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell, 169(1), 132-147.e16, 2017.
- Bourgeois B, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications, 16(1), 5672, 2025.
- Bourgeois B, Madl T. Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Letters, 592(12), 2083-2097, 2018.
- Zhang C, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging, 12(2), 1272-1284, 2020.
- Hu Z, et al. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in Bioengineering and Biotechnology, 13, 1729166, 2026.
- Huang Y, et al. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Frontiers in Bioengineering and Biotechnology, 9, 677576, 2021.
- Li Y, et al. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Experimental Gerontology, 195, 112522, 2024.
- Han X, et al. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. Journal of Cellular and Molecular Medicine, 26(11), 3269-3280, 2022.
- Liu Y, et al. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 396(10), 2393-2403, 2023.
- Putavet DA, et al. Abstract IA002: Targeting senescence heterogeneity against cancer therapy-resistance and metastases. Cancer Research, 81(5_Supplement), IA002, 2021.
- Meng J, et al. Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis. JCI Insight, 6(23), e146334, 2021.
- Krimpenfort P, Berns A. Rejuvenation by Therapeutic Elimination of Senescent Cells. Cell, 169(1), 3-5, 2017.
- Mandal R, et al. FOXO4 interacts with p53 TAD and CRD and inhibits its binding to DNA. Protein Science, 31(5), e4287, 2022.
- Kong YX, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications Biology, 8(1), 299, 2025.
- van Willigenburg H, de Keizer PLJ, de Bruin RWF. Cellular senescence as a therapeutic target to improve renal transplantation outcome. Pharmacological Research, 130, 322-330, 2018.
- Putavet D, et al. Abstract P1-19-02: Repurposing the FOXO4 senolytic against triple-negative breast cancer. Cancer Research, 82(4_Supplement), P1-19-02, 2022.
- Nwankwo N, Okafor I. Bioinformatics procedure for investigating senolytic (anti-aging) agents: A digital signal processing technique. Aging Medicine, 6(4), 338-346, 2024.
- Timucin E, et al. Novel Senolytic Peptides. United States Patent Application, US20200255489A1, 2020.
Preguntas de Investigación Relacionadas
Desea la revisión completa de la investigación?
Ver Página Completa de Investigación de Foxo4 Dri→SOLO PARA USO EN INVESTIGACIÓN
Este contenido se proporciona solo para fines educativos e informativos. Los productos se suministran exclusivamente para estudios in vitro y no son medicamentos, fármacos ni suplementos. No están aprobados por la FDA para prevenir, tratar o curar ninguna condición.